Commodore Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Commodore Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,079,756	Closed	-$3.85M	–	30
2022 Q1	$3.85M	Hold	3,079,756	–	–	0.86%	22
2021 Q4	$3.57M	Hold	3,079,756	–	–	0.83%	22
2021 Q3	$5.91M	Buy	3,079,756 +150,309	+5%	+$296K	1.56%	21
2021 Q2	$6.86M	Buy	2,929,447 +57,823	+2%	+$139K	2.39%	17
2021 Q1	$7.78M	Buy	2,871,624 +1,105,723	+63%	+$3.27M	3.1%	14
2020 Q4	$4.27M	Buy	+1,765,901	New	+$4.02M	2.32%	21

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Commodore Capital's GNCA Position: Q2 2022 in Review

Commodore Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 3,079,756 shares — an estimated $3.85M sold.

Commodore Capital first reported a position in GNCA in Q4 2020 and held it in 6 quarters. The position peaked at $7.78M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Commodore Capital reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Commodore Capital sold 3,079,756 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $3.85M.
Commodore Capital first reported a position in Genocea Biosciences, Inc. in Q4 2020 and held it in 6 quarters.
Commodore Capital's Genocea Biosciences, Inc. position peaked at $7.78M in Q1 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.